Abstract
The challenge of Inotuzumab ozogamicin treatment as “bridge to transplant” in relapsed/refractory B cell-acute lymphoblastic leukemia
Highlights
Despite improved outcome over the past 30 years, the prognosis for adults with relapsed or refractory acute lymphoblastic leukemia (ALL) remains poor
On the basis of our clinical experience and the previously reported data, we have proposed a strategy in order to minimize veno-occlusive disease (VOD) risk providing accurate selection of transplant candidates, choice of conditioning regimens without full dose of alkylating agents, monitoring of liver stiffness and reserving defibrotide prophylaxis in patients with persisting risk factors for VOD
We report a cases series of 4 patients with relapse/refractory ALL who were treated with InO and underwent hematopoietic stem cell transplantation (HSCT), with the aim of describing VOD risk factors and management of hepatotoxicity linked to Inotuzumab
Summary
On the basis of our clinical experience and the previously reported data, we have proposed a strategy in order to minimize VOD risk providing accurate selection of transplant candidates, choice of conditioning regimens without full dose of alkylating agents, monitoring of liver stiffness and reserving defibrotide prophylaxis in patients with persisting risk factors for VOD.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
